[go: up one dir, main page]

EP2892510A4 - Composés bolaamphiphiles, compositions et leurs utilisations - Google Patents

Composés bolaamphiphiles, compositions et leurs utilisations

Info

Publication number
EP2892510A4
EP2892510A4 EP13834981.6A EP13834981A EP2892510A4 EP 2892510 A4 EP2892510 A4 EP 2892510A4 EP 13834981 A EP13834981 A EP 13834981A EP 2892510 A4 EP2892510 A4 EP 2892510A4
Authority
EP
European Patent Office
Prior art keywords
compositions
bolaamphiphilic compounds
bolaamphiphilic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP13834981.6A
Other languages
German (de)
English (en)
Other versions
EP2892510A1 (fr
Inventor
Charles Linder
Eliahu Heldman
Sarina Grinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAUREN SCIENCES LLC
Original Assignee
LAUREN SCIENCES LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LAUREN SCIENCES LLC filed Critical LAUREN SCIENCES LLC
Publication of EP2892510A1 publication Critical patent/EP2892510A1/fr
Publication of EP2892510A4 publication Critical patent/EP2892510A4/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP13834981.6A 2012-09-04 2013-09-04 Composés bolaamphiphiles, compositions et leurs utilisations Pending EP2892510A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261696789P 2012-09-04 2012-09-04
PCT/US2013/057956 WO2014039501A1 (fr) 2012-09-04 2013-09-04 Composés bolaamphiphiles, compositions et leurs utilisations

Publications (2)

Publication Number Publication Date
EP2892510A1 EP2892510A1 (fr) 2015-07-15
EP2892510A4 true EP2892510A4 (fr) 2016-06-01

Family

ID=50237566

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13834981.6A Pending EP2892510A4 (fr) 2012-09-04 2013-09-04 Composés bolaamphiphiles, compositions et leurs utilisations

Country Status (5)

Country Link
EP (1) EP2892510A4 (fr)
AU (4) AU2013312908A1 (fr)
CA (2) CA2883784C (fr)
IL (3) IL237541B (fr)
WO (1) WO2014039501A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3018945A1 (fr) * 2015-04-16 2016-10-20 Lauren Sciences Llc Compositions, composes bolaamphiphiles, et leurs utilisations
CA3150779A1 (fr) * 2019-08-12 2021-02-18 Integrated Nanotherapeutics Inc. Lipides pour l'administration d'un materiau charge, leurs formulations et leur procede de fabrication

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162319A0 (en) * 2001-12-04 2005-11-20 Univ Ben Gurion Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
WO2006072943A2 (fr) * 2005-01-03 2006-07-13 Ben Gurion University Of The Negev Research And Development Authority Particles nano et mesometriques comprenant un noyau inorganique, leur procede de fabrication et leurs applications
EP2427175B1 (fr) 2009-05-04 2018-08-29 Ben-gurion University Of The Negev Research And Development Authority Particules de dimension nanométrique comprenant des amphiphiles à têtes multiples pour une administration ciblée de médicament

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PAOLINO ET AL: "Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 353, no. 1-2, 28 November 2007 (2007-11-28), pages 233 - 242, XP022513723, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2007.11.037 *
POPOV MARY ET AL: "Site-directed decapsulation of bolaamphiphilic vesicles with enzymatic cleavable surface groups", JOURNAL OF CONTROLLED RELEASE, vol. 160, no. 2, 29 December 2011 (2011-12-29), pages 306 - 314, XP028926636, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2011.12.022 *
S. GRINBERG ET AL: "Synthesis of novel cationic bolaamphiphiles from vernonia oil and their aggregated structures", CHEMISTRY AND PHYSICS OF LIPIDS., vol. 153, no. 2, 1 June 2008 (2008-06-01), IR, pages 85 - 97, XP055565983, ISSN: 0009-3084, DOI: 10.1016/j.chemphyslip.2008.01.006 *

Also Published As

Publication number Publication date
AU2022200494B2 (en) 2025-08-21
AU2020203496A1 (en) 2020-06-18
CA2883784C (fr) 2024-05-14
IL237541A0 (en) 2015-04-30
CA3233929A1 (fr) 2014-03-13
EP2892510A1 (fr) 2015-07-15
IL280316B (en) 2021-08-31
IL237541B (en) 2019-07-31
AU2018203992B2 (en) 2020-02-27
AU2013312908A1 (en) 2015-03-26
AU2018203992A1 (en) 2018-06-21
AU2022200494A1 (en) 2022-02-24
WO2014039501A1 (fr) 2014-03-13
IL267888B (en) 2021-02-28
IL280316A (en) 2021-03-01
AU2020203496B2 (en) 2021-10-28
CA2883784A1 (fr) 2014-03-13
IL267888A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
EP2888238A4 (fr) Composés benzocyclo-octyne et leurs utilisations
EP2906256A4 (fr) Composés anti-sens sélectifs et leurs utilisations
EP2906255A4 (fr) Composés anti-sens et leurs utilisations
EP2635285A4 (fr) Composés hétéroaryle et leurs utilisations
EP2635284A4 (fr) Composés hétérocycliques et leurs utilisations
EP2575462A4 (fr) Composés hétérocycliques et leurs utilisations
EP2970307A4 (fr) Composés pyrazolo et leurs utilisations
EP2951177A4 (fr) Composés imidazopyridine et leurs utilisations
EP2991978A4 (fr) Composés bihétéroaryle et leurs utilisations
EP2792674A4 (fr) Composés d'imidazolidinedione et leurs utilisations
EP2594567A4 (fr) Composés benzène alkynyl hétérocycliques, compositions médicales et leurs utilisations
EP2968337A4 (fr) Composés hétéroaryle et utilisations associées
EP2951304A4 (fr) Composés antisens sélectifs et leurs utilisations
EP2906684A4 (fr) Composés modifiant les lymphocytes t et leurs utilisations
EP2426110A4 (fr) Composés de pyrazolylacrylonitrile et leurs utilisations
EP2678320A4 (fr) Complexes de flumazénil, compositions les comprenant et leurs utilisations
EP2885318A4 (fr) Conjugués peptides-dendrimères et leurs utilisations
EP2847318A4 (fr) Souche pesticide de flavobacterium, compositions et metabolites bioactifs et leurs utilisations
EP2771020A4 (fr) Dérivés n-acyldipeptides et leurs utilisations
EP3337486A4 (fr) Composés deutérés et leurs utilisations
EP2807160A4 (fr) Composés antifibrotiques et leurs utilisations
EP2822936A4 (fr) Dérivés d'aminoquinoléine et leurs utilisations
EP2770836A4 (fr) Formulations, compositions, métabolites de chromobacterium et leurs utilisations
EP2836499A4 (fr) Composés disaccharidiques et lipidiques de synthèse et leurs utilisations
EP2935283A4 (fr) Inhibiteurs de la glycosidase et leurs utilisations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150407

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160504

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/51 20060101AFI20160428BHEP

Ipc: A61K 38/18 20060101ALI20160428BHEP

Ipc: A61K 9/133 20060101ALI20160428BHEP

Ipc: A61P 25/28 20060101ALI20160428BHEP

Ipc: A61P 25/16 20060101ALI20160428BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180125